GlassScriptPhysician profile
Rosalind Moore Dulan
NPI 1265420525
$3,055.60
in general payments reported to CMS, 2019-2025
27 companies · $376 in 2025
The $376 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $259 · 2021: $856 · 2022: $632 · 2023: $295 · 2024: $287 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $782.61 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $360.94 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $262.91 | 2019-2025 | Wegovy |
| Astellas Pharma US INC | $244.27 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.00 | 2020-2024 | Synjardy, Jardiance, Tradjenta |
| Lilly USA, LLC | $187.91 | 2019-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $180.82 | 2022-2025 | |
| Glaxosmithkline, LLC. | $126.73 | 2022-2025 | Trelegy Ellipta |
| Currax Pharmaceuticals LLC | $106.85 | 2021-2023 | Contrave, Nexlizet, Nexletol |
| Angiodynamics, INC. | $86.54 | 2021 | |
| Sanofi-Aventis U.S. LLC | $66.56 | 2019-2022 | |
| Abbvie INC. | $52.86 | 2022-2024 | Vraylar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.34 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.06 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $32.43 | 2024 | Voquezna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $32.22 | 2022-2023 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $30.74 | 2023 | Quviviq |
| Amgen INC. | $29.25 | 2019-2022 | |
| Pulmonx Corporation | $28.30 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $26.60 | 2022-2025 | Zoryve |
| Otsuka America Pharmaceutical, INC. | $18.08 | 2024 | Rexulti |
| Insulet Corporation | $17.87 | 2025 | Omnipod |
| Mannkind Corporation | $15.79 | 2019 | |
| Abbott Laboratories | $15.68 | 2022 | |
| Allergan, INC. | $15.07 | 2020 | |
| Amarin Pharma, INC. | $14.68 | 2019 | |
| Merck Sharp & Dohme LLC | $13.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosalind Dulan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.